NAMSA Acquires Labcorp's Early Development Medical Device Testing Business
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy LH?
Source: Newsfilter
- Strategic Acquisition: NAMSA has completed the acquisition of Labcorp's Early Development medical device testing business, further solidifying its leadership position in the global medical device testing sector and expected to accelerate time-to-market for MedTech manufacturers.
- Service Expansion: This acquisition allows NAMSA to assume Labcorp's U.S. portfolio, including biocompatibility, microbiological, analytical testing, and preclinical research services, enhancing its capability to provide comprehensive solutions to over 3,000 MedTech companies.
- Client Transition Assurance: NAMSA CEO Brian Smith noted that the company will ensure a smooth transition for Labcorp's medical device clients, maintaining the high level of expertise and customer service that current NAMSA clients expect, which will enhance customer satisfaction and loyalty.
- Industry Consolidation: This transaction marks NAMSA's tenth acquisition since becoming an ARCHIMED company, demonstrating its ongoing commitment to integration and innovation in the medical device industry, which is expected to drive future business growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 254.020
Low
270.00
Averages
304.45
High
325.00
Current: 254.020
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beware of Profit Traps: Analysis of Three Companies
- Steven Madden (SHOO): With a muted 17% annual revenue growth over the past five years, demand has lagged behind consumer discretionary peers, and a low free cash flow margin of 5.1% constrains its ability to self-fund growth and return capital to shareholders.
- Concrete Pumping (BBCP): The company has seen a 5.7% annual revenue decline over the last two years as customers postponed purchases, leading to a concerning 47.7% annual drop in earnings per share, while trading at $7.79 per share with a high forward P/E of 53.
- Labcorp (LH): Annual sales have declined by 1.6% over the past five years, indicating a struggle to connect with the market, and the absence of organic revenue growth may force reliance on acquisitions for expansion, with a current stock price of $255.05 and a forward P/E of 13.9.
- Market Trends: The market is rapidly separating quality stocks from expensive ones, with AI technologies disrupting sectors unexpectedly, necessitating careful investment choices to avoid profit traps.
See More
Labcorp Expands Collaboration with Epic for Enhanced Diagnostic Integration
- Collaboration Expansion: Labcorp's expanded collaboration with Epic allows its full test menu to be accessible through Epic's Aura platform, streamlining lab ordering for clinicians and enhancing access to diagnostic innovations for hospitals and health systems.
- Complexity Reduction: By leveraging Epic's Aura, Labcorp reduces the time, cost, and maintenance typically required for lab integrations, enabling health systems to access new tests more quickly and improving overall operational efficiency.
- Clinical Benefits: The integration allows clinicians to easily order the right tests directly within their Epic workflows, ensuring patients receive accurate results faster, thereby enhancing the quality of patient care.
- Foundation for Innovation: Labcorp's Executive Vice President Bryan Vaughn stated that this collaboration reflects the company's investment in meeting the evolving needs of hospitals and health systems, aiming to support future innovations through simplified lab integrations.
See More
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Labcorp (LH) Q1 2026 Earnings Call Transcript
See More
Labcorp Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Labcorp reported Q1 revenue of $3.5 billion, a 6% increase year-over-year, with adjusted earnings per share rising 11%, indicating strong momentum in both Diagnostics and Central Laboratory businesses, enhancing market competitiveness.
- Strategic Collaboration Expansion: The company announced a nationwide strategic collaboration with the Children's Hospital of Philadelphia to provide advanced diagnostics for pediatric patients, while completing the acquisition of select assets from Crouse Health's Laboratory Alliance, further solidifying its market position.
- Strong Consumer Health Performance: The Consumer Health segment delivered double-digit growth, with the MyLabcorp mobile app set to launch in May, featuring an AI assistant to simplify appointment scheduling and payments, which is expected to enhance customer experience and market share.
- Optimistic Financial Outlook: The company raised the midpoint of its 2026 enterprise revenue and EPS guidance by approximately $30 million and $0.13, respectively, expecting enterprise revenue growth of 5% to 6.1%, reflecting confidence in future performance.
See More
Labcorp Q1 Earnings Exceed Expectations
- Earnings Beat: Labcorp reported a Q1 non-GAAP EPS of $4.25, beating expectations by $0.13, which underscores the company's strong profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenue of $3.54 billion, a 5.7% year-over-year increase, exceeding expectations by $30 million, indicating its sustained competitive strength and business expansion capabilities.
- Guidance Raised: Labcorp raised its full-year enterprise revenue guidance to 5.0% to 6.1%, with the midpoint up 20 basis points, and adjusted EPS guidance of $17.70 to $18.35, surpassing the $17.79 consensus by 13 cents, reflecting confidence in future performance.
- Positive Stock Reaction: Following the earnings release, Labcorp's shares rose by 2.3%, demonstrating market recognition of its financial performance and outlook, potentially attracting more investor interest.
See More
Beware of Profit Traps: Analysis of Three Companies
- Steven Madden (SHOO): With a muted 17% annual revenue growth over the past five years, demand has lagged behind consumer discretionary peers, and a low free cash flow margin of 5.1% constrains its ability to self-fund growth and return capital to shareholders.
- Concrete Pumping (BBCP): The company has seen a 5.7% annual revenue decline over the last two years as customers postponed purchases, leading to a concerning 47.7% annual drop in earnings per share, while trading at $7.79 per share with a high forward P/E of 53.
- Labcorp (LH): Annual sales have declined by 1.6% over the past five years, indicating a struggle to connect with the market, and the absence of organic revenue growth may force reliance on acquisitions for expansion, with a current stock price of $255.05 and a forward P/E of 13.9.
- Market Trends: The market is rapidly separating quality stocks from expensive ones, with AI technologies disrupting sectors unexpectedly, necessitating careful investment choices to avoid profit traps.
See More
Labcorp Expands Collaboration with Epic for Enhanced Diagnostic Integration
- Collaboration Expansion: Labcorp's expanded collaboration with Epic allows its full test menu to be accessible through Epic's Aura platform, streamlining lab ordering for clinicians and enhancing access to diagnostic innovations for hospitals and health systems.
- Complexity Reduction: By leveraging Epic's Aura, Labcorp reduces the time, cost, and maintenance typically required for lab integrations, enabling health systems to access new tests more quickly and improving overall operational efficiency.
- Clinical Benefits: The integration allows clinicians to easily order the right tests directly within their Epic workflows, ensuring patients receive accurate results faster, thereby enhancing the quality of patient care.
- Foundation for Innovation: Labcorp's Executive Vice President Bryan Vaughn stated that this collaboration reflects the company's investment in meeting the evolving needs of hospitals and health systems, aiming to support future innovations through simplified lab integrations.
See More
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Labcorp (LH) Q1 2026 Earnings Call Transcript
See More
Labcorp Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Labcorp reported Q1 revenue of $3.5 billion, a 6% increase year-over-year, with adjusted earnings per share rising 11%, indicating strong momentum in both Diagnostics and Central Laboratory businesses, enhancing market competitiveness.
- Strategic Collaboration Expansion: The company announced a nationwide strategic collaboration with the Children's Hospital of Philadelphia to provide advanced diagnostics for pediatric patients, while completing the acquisition of select assets from Crouse Health's Laboratory Alliance, further solidifying its market position.
- Strong Consumer Health Performance: The Consumer Health segment delivered double-digit growth, with the MyLabcorp mobile app set to launch in May, featuring an AI assistant to simplify appointment scheduling and payments, which is expected to enhance customer experience and market share.
- Optimistic Financial Outlook: The company raised the midpoint of its 2026 enterprise revenue and EPS guidance by approximately $30 million and $0.13, respectively, expecting enterprise revenue growth of 5% to 6.1%, reflecting confidence in future performance.
See More
Labcorp Q1 Earnings Exceed Expectations
- Earnings Beat: Labcorp reported a Q1 non-GAAP EPS of $4.25, beating expectations by $0.13, which underscores the company's strong profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenue of $3.54 billion, a 5.7% year-over-year increase, exceeding expectations by $30 million, indicating its sustained competitive strength and business expansion capabilities.
- Guidance Raised: Labcorp raised its full-year enterprise revenue guidance to 5.0% to 6.1%, with the midpoint up 20 basis points, and adjusted EPS guidance of $17.70 to $18.35, surpassing the $17.79 consensus by 13 cents, reflecting confidence in future performance.
- Positive Stock Reaction: Following the earnings release, Labcorp's shares rose by 2.3%, demonstrating market recognition of its financial performance and outlook, potentially attracting more investor interest.
See More
